Francois Ghiringhelli1, Audrey Hennequin2, Antoine Drouillard3, Côme Lepage4, Jean Faivre4, Anne-Marie Bouvier4. 1. Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France; National Institute of Health and Medical Research, INSERM, UMR-866 University of Burgundy, Dijon, France. Electronic address: fghiringhelli@cgfl.fr. 2. Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France. 3. CHRU (University Hospital), Dijon, France; Digestive Cancer Registry of Burgundy, Dijon, France. 4. National Institute of Health and Medical Research, INSERM, UMR-866 University of Burgundy, Dijon, France; CHRU (University Hospital), Dijon, France; Digestive Cancer Registry of Burgundy, Dijon, France.
Abstract
BACKGROUND: Epidemiological data on synchronous and metachronous metastatic colon cancer are scarce. We assessed epidemiological characteristics and survival in synchronous and metachronous metastatic colon cancer in a French population. METHODS: Our study included 932 cases of metastatic colon cancer diagnosed in 1999-2010 and registered in a population-based cancer registry; 758 were synchronous colon metastases and 174 metachronous metastases from resected primary colon cancers diagnosed in 1999-2005. Univariate relative survival was calculated and a multivariate model with proportional hazard applied to net survival by interval was used. RESULTS: Mean age at diagnosis was 71.1 years for patients with metachronous metastasis and 71.4 years for those with synchronous metastasis (p=0.818). Patients with metachronous metastasis were more likely to have R0 resection (Odds Ratio: 3.05 [1.96-4.76], p<0.001) than patients with synchronous metastasis. Five-year relative survival was 7.2% for synchronous metastasis and 17.6% for metachronous metastasis (p<0.001), but did not differ significantly for patients with R0 resection (47.3% and 61.5% respectively, p=0.120). For patients not receiving chemotherapy risk of death was significantly lower in the metachronous metastasis group (Hazard Ratio=0.44 [0.32-0.60], p<0.001). CONCLUSIONS: On a population basis, synchronous metastasis is an independent poor prognostic factor in colon cancer. Chemotherapy and resection of all metastatic sites significantly improved the outcome in patients with synchronous metastasis.
BACKGROUND: Epidemiological data on synchronous and metachronous metastatic colon cancer are scarce. We assessed epidemiological characteristics and survival in synchronous and metachronous metastatic colon cancer in a French population. METHODS: Our study included 932 cases of metastatic colon cancer diagnosed in 1999-2010 and registered in a population-based cancer registry; 758 were synchronous colon metastases and 174 metachronous metastases from resected primary colon cancers diagnosed in 1999-2005. Univariate relative survival was calculated and a multivariate model with proportional hazard applied to net survival by interval was used. RESULTS: Mean age at diagnosis was 71.1 years for patients with metachronous metastasis and 71.4 years for those with synchronous metastasis (p=0.818). Patients with metachronous metastasis were more likely to have R0 resection (Odds Ratio: 3.05 [1.96-4.76], p<0.001) than patients with synchronous metastasis. Five-year relative survival was 7.2% for synchronous metastasis and 17.6% for metachronous metastasis (p<0.001), but did not differ significantly for patients with R0 resection (47.3% and 61.5% respectively, p=0.120). For patients not receiving chemotherapy risk of death was significantly lower in the metachronous metastasis group (Hazard Ratio=0.44 [0.32-0.60], p<0.001). CONCLUSIONS: On a population basis, synchronous metastasis is an independent poor prognostic factor in colon cancer. Chemotherapy and resection of all metastatic sites significantly improved the outcome in patients with synchronous metastasis.
Authors: Julian Walter Holch; Maximilian Demmer; Charlotte Lamersdorf; Marlies Michl; Christoph Schulz; Jobst Christian von Einem; Dominik Paul Modest; Volker Heinemann Journal: Visc Med Date: 2017-02-07
Authors: R L Eefsen; P B Vermeulen; I J Christensen; O D Laerum; M B Mogensen; H C Rolff; G G Van den Eynden; G Høyer-Hansen; K Osterlind; B Vainer; M Illemann Journal: Clin Exp Metastasis Date: 2015-03-31 Impact factor: 5.150
Authors: Kyu-Pyo Kim; Jeong-Eun Kim; Yong Sang Hong; Sung-Min Ahn; Sung Min Chun; Seung-Mo Hong; Se Jin Jang; Chang Sik Yu; Jin Cheon Kim; Tae Won Kim Journal: Cancer Res Treat Date: 2016-07-04 Impact factor: 4.679
Authors: H Lote; I Spiteri; L Ermini; A Vatsiou; A Roy; A McDonald; N Maka; M Balsitis; N Bose; M Simbolo; A Mafficini; A Lampis; J C Hahne; F Trevisani; Z Eltahir; G Mentrasti; C Findlay; E A J Kalkman; M Punta; B Werner; S Lise; A Aktipis; C Maley; M Greaves; C Braconi; J White; M Fassan; A Scarpa; A Sottoriva; N Valeri Journal: Ann Oncol Date: 2017-06-01 Impact factor: 32.976
Authors: Michael P Achiam; Vibeke B Løgager; Bjørn Skjoldbye; Jakob M Møller; Torben Lorenzen; Vera L Rasmussen; Henrik S Thomsen; Talie H Mollerup; Cecilie Okholm; Jacob Rosenberg Journal: PeerJ Date: 2016-01-14 Impact factor: 2.984
Authors: Felipe José Fernandez Coimbra; Heber Salvador de Castro Ribeiro; Márcio Carmona Marques; Paulo Herman; Rubens Chojniak; Antonio Nocchi Kalil; Evanius Garcia Wiermann; Sandro Roberto de Araújo Cavallero; Fabricio Ferreira Coelho; Paulo Henrique de Souza Fernandes; Anderson Arantes Silvestrini; Maria Fernanda Arruda Almeida; Antônio Luis Eiras de Araújo; Marcos Pitombo; Heberton Medeiros Teixeira; Fábio Luiz Waechter; Fábio Gonçalves Ferreira; Alessandro Landskron Diniz; Giuseppe D'Ippolito; Giuseppe D'Ippolito; Maria Dirlei F de Sousa Begnami; Gabriel Prolla; Silvio Márcio Pegoraro Balzan; Thiago Bueno de Oliveira; Luís Arnaldo Szultan; Javier Lendoire; Orlando Jorge Martins Torres Journal: Arq Bras Cir Dig Date: 2015 Nov-Dec
Authors: Nina D Arhin; Chan Shen; Christina E Bailey; Lea K Matsuoka; Alexander T Hawkins; Andreana N Holowatyj; Kristen K Ciombor; Michael B Hopkins; Timothy M Geiger; Audrey E Kam; Marc T Roth; Cody M Lebeck Lee; Michael Lapelusa; Arvind Dasari; Cathy Eng Journal: Cancer Med Date: 2021-06-16 Impact factor: 4.452